Cold agglutinin disease and autoimmune hemolytic anemia with pulmonary embolism as a presentation of COVID-19 infection

Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, 323, 1061, 10.1001/jama.2020.1585 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Fan, 2020, Hematologic parameters in patients with COVID-19 infection, Am J Hematol, 95, E131, 10.1002/ajh.25774 Deng, 2020, Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study, Chin Med J, 133, 1261, 10.1097/CM9.0000000000000824 Klok, 2020, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb Res, 191, 145, 10.1016/j.thromres.2020.04.013 Berentsen, 2006, Primary chronic cold agglutinin disease: a population based clinical study of 86 patients, Haematologia, 91, 460 Berentsen, 2012, Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia, Blood Rev, 26, 107, 10.1016/j.blre.2012.01.002 Randen, 2014, Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma, Haematologica, 99, 497, 10.3324/haematol.2013.091702 Gehrs, 2002, Autoimmune hemolytic anemia, Am J Hematol, 69, 258, 10.1002/ajh.10062 Cui, 2020, Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia, J Thromb Haemost, 18, 1421, 10.1111/jth.14830 Thachil, 2020, ISTH interim guidance on recognition and management of coagulopathy in COVID-19, J Thromb Haemost, 18, 1023, 10.1111/jth.14810 Berentsen, 2018, How I manage patients with cold agglutinin disease, Br J Haematol, 181, 320, 10.1111/bjh.15109 Plosker, 2003, Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia, Drugs, 63, 803, 10.2165/00003495-200363080-00005 Cattaneo, 2006, Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments, Leuk Lymphoma, 47, 1013, 10.1080/10428190500473113 Makatsori, 2014, Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes, QJM, 107, 821, 10.1093/qjmed/hcu094 Wolach, 2010, Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature, Medicine, 89, 308, 10.1097/MD.0b013e3181f2caef